thalidomide and Acute Disease studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Research Excerpts

Excerpt	Relevance	Reference
"To improve the outcome of allogeneic stem cell transplantation (allo-SCT) in multiple myeloma as part of first-line treatment, we prospectively investigated the feasibility and efficacy of lenalidomide maintenance."	9.15	Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. ( Bruijnen, CP; Cornelisse, PB; Cornelissen, JJ; Emmelot, M; Huisman, C; Huls, G; Janssen, JJ; Kersten, MJ; Kneppers, E; Lokhorst, HM; Meijer, E; Minnema, MC; Mutis, T; Sonneveld, P; van der Holt, B; Zweegman, S, 2011)
"To study the efficacy of thalidomide for treating acute leukemia (AL)."	9.10	[The short-term outcomes of patients with acute leukemia treated by thalidomide]. ( Li, YG; Liu, YF; Mu, HR; Sui, HT; Wang, ML; Wu, HG, 2003)
"This article reviews the historical development of thalidomide as an immunosuppressive agent and the current state of knowledge of thalidomide as an anti-graft-versus-host disease (GVHD) agent."	8.78	The potential use of thalidomide in the therapy of graft-versus-host disease--a review of clinical and laboratory information. ( Proctor, SJ; Wood, PM, 1990)
" Hence, thalidomide (100, 200 and 400 mg/kg) was herein administered to mice to evaluate possible protection against seizures induced by the systemic administration of neurotoxins: 10 mg/kg of 4-aminopyridine (4-AP), 90 mg/kg of pentylenetetrazol (PTZ), or 380 mg/kg of pilocarpine."	7.88	Thalidomide protects against acute pentylenetetrazol and pilocarpine-induced seizures in mice. ( Campos-Rodriguez, C; Islas-Espinoza, AM; San Juan, ER, 2018)
"Pretreatment with pomalidomide significantly reduced the plasma levels of amylase and lipase; the histological injury; and the expression of TNF-α, IL-1β, monocyte chemotactic protein-1 (MCP-1), and inducible nitric oxide synthase (iNOS) in cerulein-induced acute pancreatitis."	7.77	Pomalidomide suppresses cerulein-induced acute pancreatitis in mice. ( Chen, C; Chen, SH; Chiu, TH; Huang, YT; Tsai, MJ, 2011)
"Sixty patients with advanced multiple myeloma received 2-6 monthly treatment courses combining hyperfractionated cyclophosphamide (300 mg/m2 i."	6.71	Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. ( Berdel, WE; Bisping, G; Dominé, N; Fenk, R; Heinecke, A; Hentrich, M; Innig, G; Kienast, J; Koch, OM; Kropff, MH; Lang, N; Mitterer, M; Ostermann, H; Straka, C; Südhoff, T, 2003)
"Thalidomide was used to treat acute (n=21) or chronic (n=59) graft-vs-host disease (GVHD) in 80 haematopoietic stem cell allograft recipients after failure to respond to the combination of cyclosporine and corticosteroids with or without other agents."	5.32	Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease. ( Atra, A; Goyal, S; Horton, C; Kulkarni, S; Mehta, J; Meller, S; Ortin, M; Pinkerton, CR; Powles, R; Rudin, C; Sankpal, S; Saso, R; Singhal, S; Sirohi, B; Treleaven, J, 2003)
"To improve the outcome of allogeneic stem cell transplantation (allo-SCT) in multiple myeloma as part of first-line treatment, we prospectively investigated the feasibility and efficacy of lenalidomide maintenance."	5.15	Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. ( Bruijnen, CP; Cornelisse, PB; Cornelissen, JJ; Emmelot, M; Huisman, C; Huls, G; Janssen, JJ; Kersten, MJ; Kneppers, E; Lokhorst, HM; Meijer, E; Minnema, MC; Mutis, T; Sonneveld, P; van der Holt, B; Zweegman, S, 2011)
"To study the efficacy of thalidomide for treating acute leukemia (AL)."	5.10	[The short-term outcomes of patients with acute leukemia treated by thalidomide]. ( Li, YG; Liu, YF; Mu, HR; Sui, HT; Wang, ML; Wu, HG, 2003)
" Thalidomide is nowadays used for the treatment of several conditions including multiple myeloma (MM)."	4.88	Thalidomide-induced acute cholestatic hepatitis: case report and review of the literature. ( Gonçalves, R; Lopes, J; Macedo, G; Sobrinho Simões, M; Vilas-Boas, F, 2012)
" Among the putative inhibitors of angiogenesis, thalidomide has demonstrated a considerable efficacy in myelodysplastic syndromes (MDS) and AML with overall response rates up to 56% and 25%, respectively."	4.82	Thalidomide for the treatment of acute myeloid leukemia. ( Berdel, WE; Bieker, R; Kessler, T; Kienast, J; Mesters, RM; Padró, T; Steins, MB, 2003)
"This article reviews the historical development of thalidomide as an immunosuppressive agent and the current state of knowledge of thalidomide as an anti-graft-versus-host disease (GVHD) agent."	4.78	The potential use of thalidomide in the therapy of graft-versus-host disease--a review of clinical and laboratory information. ( Proctor, SJ; Wood, PM, 1990)
" Hence, thalidomide (100, 200 and 400 mg/kg) was herein administered to mice to evaluate possible protection against seizures induced by the systemic administration of neurotoxins: 10 mg/kg of 4-aminopyridine (4-AP), 90 mg/kg of pentylenetetrazol (PTZ), or 380 mg/kg of pilocarpine."	3.88	Thalidomide protects against acute pentylenetetrazol and pilocarpine-induced seizures in mice. ( Campos-Rodriguez, C; Islas-Espinoza, AM; San Juan, ER, 2018)
" Total therapy trials (TT; TT2(-/+) thalidomide) and TT3 (TT3a with bortezomib, thalidomide; TT3b with additional lenalidomide) offered the opportunity to examine the contribution of these immune-modulatory agents to MDS-associated cytogenetic abnormalities (MDS-CA) and clinical MDS or acute leukemia ("clinical MDS/AL")."	3.79	Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma. ( Abdallah, AO; Bailey, C; Barlogie, B; Chauhan, N; Cottler-Fox, M; Crowley, J; Epstein, J; Heuck, CJ; Hoering, A; Johann, D; Muzaffar, J; Petty, N; Rosenthal, A; Sawyer, J; Sexton, R; Singh, Z; Usmani, SZ; van Rhee, F; Waheed, S; Yaccoby, S, 2013)
"Pretreatment with pomalidomide significantly reduced the plasma levels of amylase and lipase; the histological injury; and the expression of TNF-α, IL-1β, monocyte chemotactic protein-1 (MCP-1), and inducible nitric oxide synthase (iNOS) in cerulein-induced acute pancreatitis."	3.77	Pomalidomide suppresses cerulein-induced acute pancreatitis in mice. ( Chen, C; Chen, SH; Chiu, TH; Huang, YT; Tsai, MJ, 2011)
"Nine plasma cell myeloma patients spontaneously developed histologically proven autologous graft-versus-host disease (GVHD) limited predominantly to the gastrointestinal tract within 1 month of initial autologous hematopoietic cell transplantation (AHCT) using high-dose melphalan conditioning."	3.77	Spontaneous autologous graft-versus-host disease in plasma cell myeloma autograft recipients: flow cytometric analysis of hematopoietic progenitor cell grafts. ( Arfons, LM; Ataergin, SA; Barr, PM; Cooper, BW; Creger, RJ; Fu, P; Gerson, SL; Kaplan, D; Kaye, NM; Kindwall-Keller, TL; Laughlin, MJ; Lazarus, HM; Liu, F; Sommers, SR, 2011)
"Pomalidomide is an immunomodulatory derivative (IMiD) active in multiple myeloma."	3.77	Acute lung toxicity related to pomalidomide. ( Geyer, HL; Lacy, MQ; Leslie, KO; Mikhael, JR; Stewart, K; Viggiano, RW; Witzig, TE, 2011)
"Thalidomide in combination with chemotherapy is an alternative treatment option for elderly patients with AML."	2.87	Thalidomide in Combination with Chemotherapy in Treating Elderly Patients with Acute Myeloid Leukemia. ( Chen, C; Xu, W; Yang, J, 2018)
"Lenalidomide was initiated at 5 mg every other day and increased to 10 mg daily, if tolerated, in each patient."	2.84	Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic Transplantation. ( Ahmed, S; Alousi, AM; Bassett, RL; Bueso-Ramos, CE; Ciurea, SO; Gulbis, AM; Jabbour, EJ; Khouri, IF; Khouri, MR; Korbling, M; Ledesma, C; Marin, D; Patel, KK; Popat, UR; Samuels, BI; Turturro, F, 2017)
"The lenalidomide combined with chemotherapy can significantly decrease the expression level of VEGF and bFGF, and enhance the remission rate of patients with AML."	2.82	[Clinical Curative Efficacy of Lenalidomide Combined with Chemotherapy for Acute Leukemia and Its Impact on VEGF]. ( Ma, LM; Ruan, LH; Yang, XW; Zhao, XQ, 2016)
"Patients ≥ 60 years of age with untreated acute myeloid leukemia received azacitidine 75 mg/m2 for 7 days followed by escalating doses of lenalidomide daily for 21 days starting on day 8 of each cycle every 6 weeks."	2.78	Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. ( Abdel-Wahab, O; Berube, C; Coutre, S; Gallegos, L; Gotlib, JR; Greenberg, P; Levine, R; Liedtke, M; Medeiros, BC; Mitchell, BS; Pollyea, DA; Zehnder, J; Zhang, B, 2013)
"Sixty patients with advanced multiple myeloma received 2-6 monthly treatment courses combining hyperfractionated cyclophosphamide (300 mg/m2 i."	2.71	Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. ( Berdel, WE; Bisping, G; Dominé, N; Fenk, R; Heinecke, A; Hentrich, M; Innig, G; Kienast, J; Koch, OM; Kropff, MH; Lang, N; Mitterer, M; Ostermann, H; Straka, C; Südhoff, T, 2003)
" Overall, adverse events were fatigue, constipation, rash, and neuropathy (grade 1 to 2 in most patients)."	2.70	Efficacy and safety of thalidomide in patients with acute myeloid leukemia. ( Berdel, WE; Bieker, R; Buechner, T; Kessler, T; Kienast, J; Kropff, M; Mesters, RM; Padró, T; Ruiz, S; Steins, MB, 2002)
"Thalidomide has one of the most notorious drug histories because of its teratogenicity."	2.40	Thalidomide in children undergoing bone marrow transplantation: series at a single institution and review of the literature. ( Graham-Pole, J; Kedar, A; Mehta, P; Skoda-Smith, S; Wingard, JR, 1999)
"Lenalidomide is a second-generation oral immunomodulatory drug that has been broadly applied in the treatment of various hematological malignancies."	1.48	Durable remission in a patient of mixed phenotype acute leukemia with Philadelphia chromosome-positive treated with nilotinib and lenalidomide: A case report. ( Lai, B; Mu, Q; Ouyang, G; Sheng, L; Wang, Y; Xu, K; Zhang, Y; Zhu, H, 2018)
"Survival for patients with multiple myeloma has increased."	1.42	Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents. ( Dimopoulos, MA; Dispenzieri, A; Gertz, MA; Kastritis, E; Kumar, S; Orlowski, R; Shah, J; Shah, RA; Terpos, E, 2015)
"Acute generalized exanthematous pustulosis (AGEP) is a diffuse pustular disorder that is primarily drug induced and characterized by acute, extensive, small, nonfollicular, sterile pustules that usually begin in intertriginous folds with widespread edema and erythema."	1.35	Acute generalized exanthematous pustulosis: an enigmatic drug-induced reaction. ( Del Rosso, JQ; Michaels, B; Mobini, N; Momin, SB, 2009)
"She was also diagnosed as having a myelofibrosis with myeloid metaplasia (MMM)."	1.33	Endolymphatic hydrops as a cause of audio-vestibular manifestations in relapsing polychondritis. ( Horii, A; Kubo, T; Mitani, K; Mizuki, M; Murata, J; Tamura, M, 2006)
"Thalidomide was used to treat acute (n=21) or chronic (n=59) graft-vs-host disease (GVHD) in 80 haematopoietic stem cell allograft recipients after failure to respond to the combination of cyclosporine and corticosteroids with or without other agents."	1.32	Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease. ( Atra, A; Goyal, S; Horton, C; Kulkarni, S; Mehta, J; Meller, S; Ortin, M; Pinkerton, CR; Powles, R; Rudin, C; Sankpal, S; Saso, R; Singhal, S; Sirohi, B; Treleaven, J, 2003)
"Thalidomide is a putative anti-angiogenesis agent that has significant anti-tumour activity in haematological malignancies with increased bone marrow angiogenesis, including multiple myeloma (MM) and myelodysplastic syndromes (MDS)."	1.32	Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia. ( Albitar, M; Cortes, J; Estey, E; Faderl, S; Giles, FJ; Kantarjian, H; Keating, M; O'Brien, S; Thomas, DA, 2003)
"Thalidomide treatment resulted in a significant reduction in tumor necrosis factor-alpha, interleukin 6 (IL-6) and IL-10 protein levels (blood) and mRNA expression (lungs)."	1.30	Effect of cytokine modulation by thalidomide on the granulomatous response in murine tuberculosis. ( Freedman, VH; Freeman, S; Kaplan, G; Laochumroonvorapong, P; Moreira, AL; Tsenova-Berkova, L; Wang, J, 1997)
"A dosage of 400 mg/kg per day of thalidomide was efficient in reducing inflammation whether given in three doses (at -24 h, -4 h and +4 h relative to LPS challenge = THAL-1; p < 0."	1.29	The effect of thalidomide and supidimide on endotoxin-induced uveitis in rats. ( Guex-Crosier, Y; Herbort, CP; Pittet, N, 1995)

Research

Studies (53)

Authors

Clinical Trials (4)

Trial Overview

Trial Outcomes

Percentage of Participants With Progression-Free Survival (PFS) at 3 Years From Initiation of Study Treatment

Timeframe	Studies, this research(%)	All Research%
pre-1990	9 (16.98)	18.7374
1990's	6 (11.32)	18.2507
2000's	15 (28.30)	29.6817
2010's	21 (39.62)	24.3611
2020's	2 (3.77)	2.80

Authors	Studies
Dorgham, N	1
Crasto, D	1
Skopit, S	1
Wang, WM	1
Shu, D	1
Jiang, YY	1
Jin, HZ	1
Braulke, F	1
Schulz, X	1
Germing, U	1
Schuler, E	1
Platzbecker, U	1
Nolte, F	1
Hofmann, WK	1
Giagounidis, A	1
Götze, K	1
Lübbert, M	1
Schlenk, RF	1
Schanz, J	1
Bacher, U	1
Ganser, A	1
Büsche, G	1
Letsch, A	1
Schafhausen, P	1
Bug, G	1
Brümmendorf, TH	1
Haas, R	1
Trümper, L	1
Shirneshan, K	1
Haase, D	1
Khouri, MR	1
Jabbour, EJ	1
Gulbis, AM	1
Turturro, F	1
Ledesma, C	1
Korbling, M	1
Samuels, BI	1
Ahmed, S	1
Alousi, AM	1
Ciurea, SO	1
Marin, D	1
Patel, KK	1
Popat, UR	1
Bueso-Ramos, CE	1
Bassett, RL	1
Khouri, IF	1
Lai, B	1
Mu, Q	1
Zhu, H	1
Wang, Y	1
Zhang, Y	3
Xu, K	1
Sheng, L	1
Ouyang, G	1
Chen, C	2
Yang, J	2
Xu, W	1
Winiczenko, R	1
Górnicki, K	1
Kaleta, A	1
Janaszek-Mańkowska, M	1
Khan, ZA	1
Singh, C	1
Khan, T	1
Ganguly, M	1
Bradsher, C	1
Goodwin, P	1
Petty, JT	1
Sandau, C	1
Bove, DG	1
Marsaa, K	1
Bekkelund, CS	1
Lindholm, MG	1
Salazar, J	1
Bermúdez, V	1
Olivar, LC	1
Torres, W	1
Palmar, J	1
Añez, R	1
Ordoñez, MG	1
Rivas, JR	1
Martínez, MS	1
Hernández, JD	1
Graterol, M	1
Rojas, J	1
Mubarak, Z	1
Humaira, A	1
Gani, BA	1
Muchlisin, ZA	1
Gremillet, C	1
Jakobsson, JG	1
Gomila, A	1
Shaw, E	1
Carratalà, J	1
Leibovici, L	1
Tebé, C	1
Wiegand, I	1
Vallejo-Torres, L	1
Vigo, JM	1
Morris, S	1
Stoddart, M	1
Grier, S	1
Vank, C	1
Cuperus, N	1
Van den Heuvel, L	1
Eliakim-Raz, N	1
Vuong, C	1
MacGowan, A	1
Addy, I	1
Pujol, M	1
Cobb, A	1
Rieger, E	1
Bell, J	1
Mallik, S	1
Zhao, Z	1
Szécsényi, Á	1
Li, G	1
Gascon, J	1
Pidko, EA	1
Zhang, GR	1
Wolker, T	1
Sandbeck, DJS	1
Munoz, M	1
Mayrhofer, KJJ	1
Cherevko, S	1
Etzold, BJM	1
Lukashuk, L	1
Yigit, N	1
Rameshan, R	1
Kolar, E	1
Teschner, D	1
Hävecker, M	1
Knop-Gericke, A	1
Schlögl, R	1
Föttinger, K	1
Rupprechter, G	1
Franconieri, F	1
Deshayes, S	1
de Boysson, H	1
Trad, S	1
Martin Silva, N	1
Terrier, B	1
Bienvenu, B	1
Galateau-Sallé, F	1
Emile, JF	1
Johnson, AC	1
Aouba, A	1
Vogt, TJ	1
Gevensleben, H	1
Dietrich, J	1
Kristiansen, G	1
Bootz, F	1
Landsberg, J	1
Goltz, D	1
Dietrich, D	1
Idorn, M	1
Skadborg, SK	1
Kellermann, L	1
Halldórsdóttir, HR	1
Holmen Olofsson, G	1
Met, Ö	1
Thor Straten, P	1
Johnson, LE	1
Brockstedt, D	1
Leong, M	1
Lauer, P	1
Theisen, E	1
Sauer, JD	1
McNeel, DG	1
Morandi, F	1
Marimpietri, D	1
Horenstein, AL	1
Bolzoni, M	1
Toscani, D	1
Costa, F	1
Castella, B	1
Faini, AC	1
Massaia, M	1
Pistoia, V	1
Giuliani, N	1
Malavasi, F	1
Qiu, J	1
Peng, S	1
Yang, A	1
Ma, Y	1
Han, L	1
Cheng, MA	1
Farmer, E	1
Hung, CF	1
Wu, TC	1
Modak, S	1
Le Luduec, JB	1
Cheung, IY	1
Goldman, DA	1
Ostrovnaya, I	1
Doubrovina, E	1
Basu, E	1
Kushner, BH	1
Kramer, K	1
Roberts, SS	1
O'Reilly, RJ	1
Cheung, NV	1
Hsu, KC	1
Salgarello, T	1
Giudiceandrea, A	1
Calandriello, L	1
Marangoni, D	1
Colotto, A	1
Caporossi, A	1
Falsini, B	1
Lefrançois, P	1
Xie, P	1
Wang, L	2
Tetzlaff, MT	1
Moreau, L	1
Watters, AK	1
Netchiporouk, E	1
Provost, N	1
Gilbert, M	1
Ni, X	1
Sasseville, D	1
Wheeler, DA	1
Duvic, M	1
Litvinov, IV	1
O'Connor, BJ	1
Fryda, NJ	1
Ranglack, DH	1
Yang, Y	2
Zhang, X	2
Grün, AL	1
Emmerling, C	1
Aumeeruddy-Elalfi, Z	1
Ismaël, IS	1
Hosenally, M	1
Zengin, G	1
Mahomoodally, MF	1
Dotsenko, A	1
Gusakov, A	1
Rozhkova, A	1
Sinitsyna, O	1
Shashkov, I	1
Sinitsyn, A	1
Hong, CE	1
Kim, JU	1
Lee, JW	1
Lee, SW	1
Jo, IH	1
Pandiyarajan, S	1
Premasudha, P	1
Kadirvelu, K	1
Wang, B	1
Luo, L	1
Wang, D	1
Ding, R	1
Hong, J	1
Caviezel, D	1
Maissen, S	1
Niess, JH	1
Kiss, C	1
Hruz, P	1
Pockes, S	1
Wifling, D	1
Keller, M	1
Buschauer, A	1
Elz, S	1
Santos, AF	1
Ferreira, IP	1
Pinheiro, CB	1
Santos, VG	1
Lopes, MTP	1
Teixeira, LR	1
Rocha, WR	1
Rodrigues, GLS	1
Beraldo, H	1
Lohar, S	1
Dhara, K	1
Roy, P	1
Sinha Babu, SP	1
Chattopadhyay, P	1
Sukwong, P	1
Sunwoo, IY	1
Lee, MJ	1
Ra, CH	1
Jeong, GT	1
Kim, SK	2
Huvinen, E	1
Eriksson, JG	1
Stach-Lempinen, B	1
Tiitinen, A	1
Koivusalo, SB	1
Malhotra, M	1
Suresh, S	1
Garg, A	1
Wei, L	1
Jiang, Y	2
Zhou, W	1
Liu, S	1
Liu, Y	1
Rausch-Fan, X	1
Liu, Z	1
Marques, WL	1
van der Woude, LN	1
Luttik, MAH	1
van den Broek, M	1
Nijenhuis, JM	1
Pronk, JT	1
van Maris, AJA	1
Mans, R	1
Gombert, AK	1
Xu, A	1
Sun, J	1
Li, J	1
Chen, W	2
Zheng, R	1
Han, Z	1
Ji, L	1
Shen, WQ	1
Bao, LP	1
Hu, SF	1
Gao, XJ	1
Xie, YP	1
Gao, XF	1
Huang, WH	1
Lu, X	1
Gostin, PF	1
Addison, O	1
Morrell, AP	1
Cook, AJMC	1
Liens, A	1
Stoica, M	1
Ignatyev, K	1
Street, SR	1
Wu, J	1
Chiu, YL	1
Davenport, AJ	1
Qiu, Z	1
Shu, J	1
Tang, D	1
Gao, X	1
Zhang, J	3
Huang, K	1
Wai, H	1
Du, K	1
Anesini, J	1
Kim, WS	1
Eastman, A	1
Micalizio, GC	1
Liang, JH	1
Huo, XK	1
Cheng, ZB	1
Sun, CP	1
Zhao, JC	1
Kang, XH	1
Zhang, TY	1
Chen, ZJ	1
Yang, TM	1
Wu, YY	1
Deng, XP	1
Zhang, YX	1
Salem, HF	1
Kharshoum, RM	1
Abou-Taleb, HA	1
AbouTaleb, HA	1
AbouElhassan, KM	1
Ohata, C	1
Ohyama, B	1
Kuwahara, F	1
Katayama, E	1
Nakama, T	1
Kobayashi, S	1
Kashiwagi, T	1
Kimura, J	1
Lin, JD	1
Liou, MJ	1
Hsu, HL	1
Leong, KK	1
Chen, YT	1
Wang, YR	1
Hung, WS	1
Lee, HY	1
Tsai, HJ	1
Tseng, CP	1
Alten, B	1
Yesiltepe, M	1
Bayraktar, E	1
Tas, ST	1
Gocmen, AY	1
Kursungoz, C	1
Martinez, A	2
Sara, Y	1
Huang, S	2
Adams, E	1
Van Schepdael, A	1
Wang, Q	1
Chung, CY	1
Yang, W	1
Yang, G	1
Chough, S	1
Chen, Y	1
Yin, B	1
Bhattacharya, R	1
Hu, Y	1
Saeui, CT	1
Yarema, KJ	1
Betenbaugh, MJ	1
Zhang, H	1
Patik, JC	1
Tucker, WJ	1
Curtis, BM	1
Nelson, MD	1
Nasirian, A	1
Park, S	1
Brothers, RM	1
Dohlmann, TL	1
Hindsø, M	1
Dela, F	1
Helge, JW	1
Larsen, S	1
Gayani, B	1
Dilhari, A	1
Wijesinghe, GK	1
Kumarage, S	1
Abayaweera, G	1
Samarakoon, SR	1
Perera, IC	1
Kottegoda, N	1
Weerasekera, MM	1
Nardi, MV	1
Timpel, M	1
Ligorio, G	1
Zorn Morales, N	1
Chiappini, A	1
Toccoli, T	1
Verucchi, R	1
Ceccato, R	1
Pasquali, L	1
List-Kratochvil, EJW	1
Quaranta, A	1
Dirè, S	1
Heo, K	1
Jo, SH	1
Shim, J	1
Kang, DH	1
Kim, JH	1
Park, JH	1
Akhtar, N	1
Saha, A	1
Kumar, V	1
Pradhan, N	1
Panda, S	1
Morla, S	1
Kumar, S	2
Manna, D	1
Wang, H	1
Xu, E	1
Yu, S	1
Li, D	1
Quan, J	1
Xu, L	1
Saslow, SA	1
Um, W	1
Pearce, CI	1
Bowden, ME	1
Engelhard, MH	1
Lukens, WL	1
Kim, DS	1
Schweiger, MJ	1
Kruger, AA	1
Adair, LS	1
Kuzawa, C	1
McDade, T	1
Carba, DB	1
Borja, JB	1
Liang, X	2
Song, W	1
Wang, K	1
Zhang, B	2
Peele, ME	1
Luo, HR	1
Chen, ZY	1
Fei, JJ	1
Du, ZJ	1
Yi, KJ	1
Im, WT	1
Kim, DW	1
Ji, X	1
Zhang, C	1
Xu, Z	1
Ding, Y	1
Song, Q	1
Li, B	2
Zhao, H	1
Lee, DW	1
Lee, H	1
Kwon, BO	1
Khim, JS	1
Yim, UH	1
Park, H	1
Park, B	1
Choi, IG	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase II Study Incorporating Bone Marrow Microenvironment (ME) - Co-Targeting Bortezomib Into Tandem Melphalan-Based Autotransplants With DTPACE for Induction/Consolidation and Thalidomide + Dexamethasone for Maintenance[NCT00572169]	Phase 3	177 participants (Actual)	Interventional	2006-11-30	Active, not recruiting
A Phase 2 Study Incorporating Bone Marrow Microenvironment (ME) Co-Targeting Bortezomib Into Tandem Melphalan-Based Autotransplants With DT PACE for Induction/Consolidation and Thalidomide + Dexamethasone for Maintenance[NCT00081939]	Phase 2	303 participants (Actual)	Interventional	2004-01-31	Completed
A Phase II Trial of GM-CSF Plus Maintenance Pembrolizumab +/- Pemetrexed After Completion of First Line Chemo-Immunotherapy in Advanced Non-Small Cell Lung Cancer Patients With PDL-1 of 1%-49%[NCT04856176]	Phase 2	83 participants (Anticipated)	Interventional	2022-01-03	Recruiting
A Phase 1-2 Study of Azacitidine in Combination With Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia[NCT00890929]	Phase 1/Phase 2	45 participants (Actual)	Interventional	2009-04-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

In patients with no confirmed Partial Response, Near Complete Response, or Complete Response, progression was defined as a >25% increase from baseline in myeloma protein production or other signs of disease progression such as hypercalcemia, etc. (NCT00081939)
Timeframe: 3 years

4-week Survival Rate

Intervention	percentage of participants (Number)
Study Treatment	77

"Early death was assessed as death within 28 days of the start of treatment" (NCT00890929)
Timeframe: 28 days

Compete Remission (CR) Rate

Intervention	percentage of subjects remaining alive (Number)
Azacitidine Followed by Lenalidomide	83

Compete Remission (CR) includes subjects with CR but incomplete recovery of blood counts (CRi). CR was assessed according to the European LeukemiaNet (ELN) guidelines, and is defined as the absence of clonal lymphocytes in the peripheral blood. (NCT00890929)
Timeframe: 12 months

Maximum Tolerated Dose (MTD) of Lenalidomide

Intervention	percentage of subjects (Number)
Azacitidine Followed by Lenalidomide	28

The maximum tolerated dose (MTD) of lenalidomide was determined in study phase 1, for use in study Phase 2 (not conducted). The outcome is reported as the dose of lenalidomide that represents the MTD. (NCT00890929)
Timeframe: 15 months

OS of Responders

Intervention	mg/day lenalidomide (oral) (Number)
Azacitidine Followed by Lenalidomide	50

OS from the start of treatment of responders (per ELN guidelines) was assessed at a median follow up of 88 weeks from the end of treatment (range, 1-120), and was censored at 1 April 2012. (NCT00890929)
Timeframe: 88 weeks (median)

Overall Response Rate (ORR)

Intervention	weeks (Median)
Azacitidine Followed by Lenalidomide	69

ORR includes subjects with CR, CRi, and partial response (PR). Responses were assessed according to the ELN guidelines. (NCT00890929)
Timeframe: 26 months

Overall Survival (OS)

Intervention	percentage of subjects (Number)
Azacitidine Followed by Lenalidomide	41

OS from the start of treatment was assessed at a median follow up of 88 weeks from the end of treatment (range, 1-120), and was censored at 1 April 2012. (NCT00890929)
Timeframe: 88 weeks (median)

Remission Duration

Intervention	weeks (Median)
Azacitidine Followed by Lenalidomide	20

Responses and remission were assessed according to the ELN guidelines. (NCT00890929)
Timeframe: 26 months

Time to CR

Intervention	weeks (Median)
Azacitidine Followed by Lenalidomide	6

CR includes subjects with CR but incomplete recovery of blood counts (CRi). Responses were assessed according to the ELN guidelines. (NCT00890929)
Timeframe: 18 weeks

Time to PR

Intervention	weeks (Median)
Azacitidine Followed by Lenalidomide	12

Responses were assessed according to the ELN guidelines. (NCT00890929)
Timeframe: 36 weeks

Article	Year
How I treat patients with myelodysplastic syndromes. Blood, 2009, Jun-18, Volume: 113, Issue:25 Topics: Acute Disease; Aged; Azacitidine; Chelation Therapy; Chromosome Deletion; Chromosomes, Human, Pair 5	2009
Thalidomide-induced acute cholestatic hepatitis: case report and review of the literature. Gastroenterologia y hepatologia, 2012, Volume: 35, Issue:8 Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Chemical and Drug Induc	2012
Thalidomide for the treatment of acute myeloid leukemia. Leukemia & lymphoma, 2003, Volume: 44, Issue:9 Topics: Acute Disease; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Bone Marrow;	2003
[Systemic treatment of cutaneous lupus erythematosus]. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2003, Volume: 1, Issue:9 Topics: Acute Disease; Administration, Oral; Adrenal Cortex Hormones; Adult; Antibodies, Monoclonal; Antimal	2003
Graft-versus-host disease. Current opinion in oncology, 1994, Volume: 6, Issue:4 Topics: Acute Disease; Adolescent; Adult; Bone Marrow Transplantation; Child; Chronic Disease; Clinical Tria	1994
Managing PLE and actinic prurigo. The Practitioner, 1997, Volume: 241, Issue:1571 Topics: Acute Disease; Anti-Inflammatory Agents; Humans; Immunosuppressive Agents; Photosensitivity Disorder	1997
Thalidomide in children undergoing bone marrow transplantation: series at a single institution and review of the literature. Pediatrics, 1999, Volume: 103, Issue:4 Topics: Acute Disease; Adolescent; Bone Marrow Transplantation; Child; Child, Preschool; Chronic Disease; Gr	1999
The potential use of thalidomide in the therapy of graft-versus-host disease--a review of clinical and laboratory information. Leukemia research, 1990, Volume: 14, Issue:5 Topics: Acute Disease; Animals; Chronic Disease; Down-Regulation; Graft vs Host Disease; Humans; Immunosuppr	1990

Article	Year
Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial. Annals of hematology, 2017, Volume: 96, Issue:6 Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antigens, CD34; Chromosome B	2017
Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2017, Volume: 23, Issue:8 Topics: Acute Disease; Aged; Allografts; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Dis	2017
Thalidomide in Combination with Chemotherapy in Treating Elderly Patients with Acute Myeloid Leukemia. Oncology research and treatment, 2018, Volume: 41, Issue:7-8 Topics: Aclarubicin; Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols;	2018
Neural computing & applications, 2018, Volume: 30, Issue:6 Topics: Activities of Daily Living; Acute Disease; Adalimumab; Adaptation, Physiological; Adenosine Triphosp	2018
[Clinical Curative Efficacy of Lenalidomide Combined with Chemotherapy for Acute Leukemia and Its Impact on VEGF]. Zhongguo shi yan xue ye xue za zhi, 2016, Volume: 24, Issue:3 Topics: Acute Disease; Antineoplastic Agents; Drug Therapy, Combination; Fibroblast Growth Factor 2; Humans;	2016
Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. Blood, 2011, Sep-01, Volume: 118, Issue:9 Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Cyclophosphamide; Cycl	2011
Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. Haematologica, 2013, Volume: 98, Issue:4 Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine;	2013
[The short-term outcomes of patients with acute leukemia treated by thalidomide]. Zhonghua nei ke za zhi, 2003, Volume: 42, Issue:5 Topics: Acute Disease; Adolescent; Adult; Aged; Angiogenesis Inhibitors; Bone Marrow; Child; Female; Humans;	2003
Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. British journal of haematology, 2003, Volume: 122, Issue:4 Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Ischem	2003
Efficacy and safety of thalidomide in patients with acute myeloid leukemia. Blood, 2002, Feb-01, Volume: 99, Issue:3 Topics: Acute Disease; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Bone Marrow; Dose-Response Relation	2002
WHO co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients. Bulletin of the World Health Organization, 1971, Volume: 45, Issue:6 Topics: Acute Disease; Adolescent; Adult; Aspirin; Clinical Trials as Topic; Humans; Leprosy; Male; Middle A	1971

Article	Year
Successful Treatment of Palmoplantar Pustulosis With Apremilast. Journal of drugs in dermatology : JDD, 2021, Nov-01, Volume: 20, Issue:11 Topics: Acute Disease; Humans; Psoriasis; Skin Diseases, Vesiculobullous; Thalidomide	2021
Recurrent generalized pustular psoriasis possibly triggered by apremilast. Chinese medical journal, 2020, May-20, Volume: 133, Issue:10 Topics: Acute Disease; Humans; Psoriasis; Skin Diseases, Vesiculobullous; Thalidomide	2020
Durable remission in a patient of mixed phenotype acute leukemia with Philadelphia chromosome-positive treated with nilotinib and lenalidomide: A case report. Medicine, 2018, Volume: 97, Issue:14 Topics: Acute Disease; Antineoplastic Agents; Drug Therapy, Combination; Humans; Induction Chemotherapy; Len	2018
Thalidomide protects against acute pentylenetetrazol and pilocarpine-induced seizures in mice. The Journal of toxicological sciences, 2018, Volume: 43, Issue:11 Topics: 4-Aminopyridine; Acute Disease; Animals; Anticonvulsants; Disease Models, Animal; Drug Therapy, Comb	2018
Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma. Blood, 2013, Jun-06, Volume: 121, Issue:23 Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acid	2013
Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma. Blood, 2013, Jun-06, Volume: 121, Issue:23 Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acid	2013
Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma. Blood, 2013, Jun-06, Volume: 121, Issue:23 Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acid	2013
Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma. Blood, 2013, Jun-06, Volume: 121, Issue:23 Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acid	2013
[Acute dyspnea, subfebrile temperatures and chills in a patient with multiple myeloma]. Medizinische Klinik, Intensivmedizin und Notfallmedizin, 2014, Volume: 109, Issue:2 Topics: Acute Disease; Aged; Comorbidity; Dexamethasone; Dyspnea; Hematopoietic Stem Cell Transplantation; H	2014
Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents. Leukemia & lymphoma, 2015, Volume: 56, Issue:6 Topics: Acute Disease; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Bortezomib;	2015
Thalidomide for the treatment of angiodysplasia in a patient with acute upper gastrointestinal haemorrhage. BMJ case reports, 2016, Jan-20, Volume: 2016 Topics: Acute Disease; Aged, 80 and over; Angiodysplasia; Angiogenesis Inhibitors; Endoscopy; Female; Gastro	2016
Durable clinical and cytogenetic remission in an elderly patient with relapsed acute myeloid leukemia treated with low-dose lenalidomide. Leukemia & lymphoma, 2009, Volume: 50, Issue:4 Topics: Acute Disease; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidin	2009
Acute generalized exanthematous pustulosis: an enigmatic drug-induced reaction. Cutis, 2009, Volume: 83, Issue:6 Topics: Acute Disease; Aged; Dexamethasone; Diagnosis, Differential; Drug Eruptions; Exanthema; Humans; Male	2009
Lenalidomide-induced acute interstitial nephritis. The oncologist, 2010, Volume: 15, Issue:9 Topics: Acute Disease; Antineoplastic Agents; Female; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; N	2010
Sudden acute leukemia transformation in a MDS patient with del(5q) in complete cytogenetic remission after lenalidomide. Leukemia research, 2011, Volume: 35, Issue:6 Topics: Acute Disease; Aged; Antineoplastic Agents; Cell Transformation, Neoplastic; Chromosome Deletion; Ch	2011
Pomalidomide suppresses cerulein-induced acute pancreatitis in mice. Journal of gastroenterology, 2011, Volume: 46, Issue:6 Topics: Acute Disease; Administration, Oral; Amylases; Animals; Ceruletide; Disease Models, Animal; Immunolo	2011
Spontaneous autologous graft-versus-host disease in plasma cell myeloma autograft recipients: flow cytometric analysis of hematopoietic progenitor cell grafts. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:7 Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Aged; Biomarkers; Boronic Acids; Bortezomib; Case-Con	2011
Acute lung toxicity related to pomalidomide. Chest, 2011, Volume: 140, Issue:2 Topics: Acute Disease; Aged; Antineoplastic Agents; Female; Humans; Lung; Lung Diseases; Male; Middle Aged;	2011
Parvovirus B19-induced type II mixed cryoglobulinemia. The American journal of medicine, 2011, Volume: 124, Issue:9 Topics: Acute Disease; Antibodies, Viral; Antineoplastic Agents; Cryoglobulinemia; Diagnosis, Differential;	2011
Lepromatous leprosy presenting as an acute polyarthritis in a Colombian immigrant in Spain. Joint bone spine, 2012, Volume: 79, Issue:2 Topics: Acute Disease; Adult; Arthritis; Biopsy; Colombia; Emigration and Immigration; Humans; Leprostatic A	2012
Thalidomide paradoxical effect on concomitant multiple myeloma and myelodysplasia. Leukemia & lymphoma, 2002, Volume: 43, Issue:6 Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B	2002
New designs for phase 2 clinical trials. Blood, 2003, Jul-15, Volume: 102, Issue:2 Topics: Acute Disease; Adenine Nucleotides; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemothe	2003
Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease. Bone marrow transplantation, 2003, Volume: 32, Issue:2 Topics: Acute Disease; Adolescent; Adrenal Cortex Hormones; Adult; Child; Child, Preschool; Chronic Disease;	2003
Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia. British journal of haematology, 2003, Volume: 123, Issue:3 Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Biomarkers; Fibroblast Growt	2003
Endolymphatic hydrops as a cause of audio-vestibular manifestations in relapsing polychondritis. Acta oto-laryngologica, 2006, Volume: 126, Issue:5 Topics: Acute Disease; Audiometry, Evoked Response; Autoimmune Diseases; C-Reactive Protein; Diagnosis, Diff	2006
Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome. Leukemia, 2006, Volume: 20, Issue:11 Topics: Acute Disease; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; J	2006
Treatment of deletion 5q acute myeloid leukemia with lenalidomide. Leukemia, 2007, Volume: 21, Issue:3 Topics: Acute Disease; Antineoplastic Agents; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5;	2007
The effect of thalidomide and supidimide on endotoxin-induced uveitis in rats. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 1995, Volume: 233, Issue:2 Topics: Acute Disease; Animals; Anterior Chamber; Aqueous Humor; Bacterial Toxins; Endotoxins; Enterotoxins;	1995
Effect of cytokine modulation by thalidomide on the granulomatous response in murine tuberculosis. Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 1997, Volume: 78, Issue:1 Topics: Acute Disease; Animals; Apoptosis; Cytokines; Female; Immunosuppressive Agents; Interleukin-10; Inte	1997
The drug treatment of leprosy. The Practitioner, 1975, Volume: 215, Issue:1288 Topics: Acute Disease; Adrenal Cortex Hormones; Aniline Compounds; Clofazimine; Dapsone; Drug Therapy, Combi	1975
Thalidomide for graft-versus-host disease after bone marrow transplantation. Lancet (London, England), 1988, Feb-13, Volume: 1, Issue:8581 Topics: Acute Disease; Adult; Bone Marrow Transplantation; Drug Administration Schedule; Graft vs Host Disea	1988
Thalidomide for severe acute graft-versus-host disease. Lancet (London, England), 1988, Sep-03, Volume: 2, Issue:8610 Topics: Acute Disease; Adolescent; Adult; Bone Marrow Transplantation; Drug Administration Schedule; Graft v	1988
Thalidomide for graft-versus-host disease. Lancet (London, England), 1988, Nov-12, Volume: 2, Issue:8620 Topics: Acute Disease; Adolescent; Adult; Bone Marrow Transplantation; Child; Chronic Disease; Female; Graft	1988
[Neuropathies caused by thalidomide]. Revue neurologique, 1985, Volume: 141, Issue:11 Topics: Acute Disease; Adult; Female; Humans; Lupus Erythematosus, Discoid; Male; Microscopy, Electron; Midd	1985
Thalidomide back in good graces--seems to help GVHD patients. Oncology (Williston Park, N.Y.), 1988, Volume: 2, Issue:9 Topics: Acute Disease; Adolescent; Adult; Bone Marrow Transplantation; Child; Child, Preschool; Chronic Dise	1988
Mechanisms of reactions in leprosy. Lancet (London, England), 1972, Sep-16, Volume: 2, Issue:7777 Topics: Acute Disease; Adrenal Cortex Hormones; Animals; Antibody Formation; Chronic Disease; Erythema Nodos	1972
Treatment of erythema nodosum leprosum with thalidomide. Lancet (London, England), 1973, Aug-11, Volume: 2, Issue:7824 Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Erythema Nodosum; Female; Humans; Leprosy; Male; Recu	1973

thalidomide and Acute Disease